|
Briefing
|
- 3D Printing Adoption – French pharmaceutical company UPSA (Union de Pharmacologie Scientifique Appliquée) bought Stratasys Fortus 450mc Production 3D Printer to revitalize manufacturing
- Improved Equipment Performance – Showed that 3D printing parts can decrease part weight by 70%, reducing machine wear-and-tear, and improving productivity and machine life
- 95% Manufacturing Cost Reduction – Replaced conventional steel arm, used to grip and open folding carton, with 3D printed arm, resulting in 95% manufacturing cost reduction
- Reducing Process Time – Created 3D printed device that sucks and blows air to remove particles from caps of Efferalgan (paracetamol), eliminating time-consuming and expensive manual visual inspection process
- Dramatically Reducing Parts Required – Reduced number of parts needed for camera mounts that help automate checking of packaging labels from 27 to two
- Immediate ROI – Achieved return on investment from cost savings in manufacturing within one year of owning new printer
|
|
Business Model and Practices
Business Model
and Practices
|
|
|
Sector
|
Healthcare/Health Sciences, Industrial Manufacturing
|
|
Organization
|
Stratasys Ltd., Union de Pharmacologie Scientifique Appliquée (UPSA)
|
|
Source
|
|
|
Original Publication Date
|
March 27, 2018
|
